Feedback / Questions
lirentelimab subcutaneous (AK002 SC) - Allakos
AK006 - Allakos
https://www.biospace.com/article/releases/allakos-provides-business-update-and-reports-second-quarter-2023-financial-results/?s=105#:~:text=Second%20Quarter%202023%20Financial%20Results,-Research%20and%20development&text=The%20decrease%20was%20primarily%20due,the%20second%20quarter%20of%202022.
Aug 10, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next